Yet another woman battling cancer has filed a permanent hair loss lawsuit against one of her chemotherapy drug’s manufacturers. The lawsuit claims that the drug, Taxotere, caused the hair loss endured during chemotherapy to last long after this treatment was over.

The plaintiffs in this permanent hair loss lawsuit, Barbara and Tim E., are a Georgia couple. After Barbara was diagnosed with cancer, she began the process of undergoing chemotherapy treatment. She was treated with Taxotere for a period of several weeks, from December 2010 through February 2011.

Like most cancer patients, Barbara went into chemotherapy knowing that she would likely lose her hair to the process. What she didn’t know was that after her chemotherapy treatment was over, she may be unable to grow her hair back.

Indeed, Barbara’s hair—over five years after chemotherapy was over—has still not properly grown back. At that point, there was nothing she could do. Hair loss is obviously a well-known side effect of chemotherapy, but many like Barbara are not warned about the risk of permanent hair loss, also known as alopecia, linked with drugs like Taxotere.

Barbara, after realizing that her hair would not grow back, decided to file a permanent hair loss lawsuit against Sanofi for failing to adequately warn her about Taxotere’s hair loss risks, and the much more permanent nature of potential hair loss. Barbara filed her permanent hair loss lawsuit on Oct. 13, 2017 in the U.S. District Court for the Eastern District of Louisiana.

The permanent hair loss lawsuit was filed on multiple counts including failure to warn, negligence, fraudulent misrepresentation and concealment, fraud and deceit, breach of express warranty, and others. Barbara’s husband Tim also filed on one count of loss of consortium.

Background of Taxotere

Taxotere (also known by its generic name, docetaxel) is manufactured and sold by Sanofi. Taxotere is one of the most popular breast cancer treatment drugs, and is also used for other cancer treatment, including lung cancer.

Taxotere was approved by the U.S. Food and Drug Administration (FDA) back in 1996, and in the two decades since its release onto the market, it has grown increasingly more popular across the country.

Taxotere fights cancer by preventing cancer cells from growing. However, the same function that prevents the rapid growth of cancer cells may also prevent a patient’s hair from growing back after chemotherapy, causing serious and even permanent Taxotere hair loss problems.

Hair loss problems are an expected part of chemotherapy treatment, but patients also generally expect that their hair will grow back after treatment is over. Unfortunately, many cancer patients have discovered after cancer treatment with certain chemotherapy drugs, including Taxotere, their hair will either not grow back or grows back with great difficulty.

Filing a Taxotere Permanent Hair Loss Lawsuit

After experiencing Taxotere permanent hair loss, also known as alopecia, a growing number of cancer patients like Barbara are filing lawsuits against drug manufacturers. According to this Taxotere permanent hair loss lawsuit and others like it, Sanofi either knew or should have known that Taxotere was linked with the risk of permanent hair loss.

If you or someone you love has suffered from serious side effects of Taxotere including alopecia,or permanent hair loss after cancer treatment, you may be able to gain some kind of financial compensation by filing a Taxotere permanent hair loss lawsuit.

Filing a Taxotere permanent hair loss lawsuit cannot take away the pain and suffering a cancer patient endures or take away the effects of alopecia, but it can help compensate for the financial expenses incurred by cancer treatment bills or even lost wages.

The Taxotere Permanent Hair Loss Lawsuit is Case No. 2:17-cv-10604-KDE-MBN, in the U.S. District Court for the Eastern District of Louisiana.